Reports

Sale

Adult Malignant Glioma Therapeutics Market

Global Adult Malignant Glioma Therapeutics Market Share, Size, Forecast: By Diseases Type: Glioblastoma Multiforme (GBM), Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Others; By Therapy Type; By Drug Class; By Route of Administration; By Treatment Centers; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Adult Malignant Glioma Therapeutics Market Outlook

The global adult malignant glioma therapeutics market size attained a value of USD 2.19 billion in 2023 driven by rising prevalence of cancer disorders. The market is anticipated to grow at a CAGR of 9.2% during the forecast period of 2024-2032 to attain a value of USD 4.85 billion by 2032.

 

adult-malignant-glioma-therapeutics-market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America and Asia Pacific to be the Significant Regional Markets for Adult Malignant Glioma Therapeutics

North America is anticipated to dominate the global market due to the presence of major product manufacturers, high research and development (R&D), growing healthcare expenditure, and trained personnel. Technological innovation is a major market driver in North America. According to the National Library of Medicine, approximately 17,000 new high-grade gliomas (HGG) cases are diagnosed in the United States each year. Primary malignant brain tumours account for approximately 3% of all cancer deaths, the majority (around 80%) of which are HGG . The rise in the incidence of the disease, a strong economy, high diagnosis rate owing to the awareness about healthcare among the population are the other major factors driving the adult malignant glioma therapeutics market.

Due to an increase in government awareness programmes and the number of generic drugs, Asia Pacific is estimated to account for the largest market share for adult malignant glioma therapeutics in the forecast period. The market's growth, however, is likely to be determined by the combined prospects in technology and opportunity in developing Asian countries such as China, Japan, India, and South Korea. The relatively large patient population requiring affordable care and improvements in health care infrastructure in rapidly developing countries that aid in the early detection of malignant gliomas are likely to drive the adult malignant glioma therapeutics market.

 

Market Segmentations

Malignant brain tumours have a profound effect on both those who receive and those who deliver the diagnosis. Malignant gliomas, the most prevalent subtype of primary brain tumours, are aggressive, highly invasive, and neurologically damaging tumours that are among the most fatal human diseases.

 

adult-malignant-glioma-therapeutics-market-by-segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The different therapies provided by the market are:

  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Others

Based on disease, the market is divided into:

  • Anaplastic Astrocytoma
  • Glioblastoma Multiforme
  • Anaplastic Oligodendroglioma
  • Others

The end-uses of the market are:

  • Speciality Clinics
  • Hospitals
  • Cancer and Radiation Therapy Centres
  • Others

The regional markets for adult malignant glioma therapeutics can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

adult-malignant-glioma-therapeutics-market-by-region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Prevalence of Cancer Related Disorders Propelling the Market Growth

The rising prevalence of cancer-related disorders worldwide and growing cases of brain tumours are the major factors driving the adult malignant glioma therapeutics market. The adoption of an unhealthy lifestyle, genetic modification/alteration, increased age, excessive exposure to radiation and family history with brain cancer are also propelling the market growth. Further, increased advancements in cancer treatment, a fast-expanding pipeline of innovative novel medications, and increased government support to accelerate the process of orphan drug approval are expected to bolster the market growth during the projection period. However, high treatment costs, loss of market exclusivity, post-patent expiration, and price reductions in branded drugs owing to competition from generic brands may impede the market growth.

Technological advancements in diagnosing glioma and analysing its progression through various imaging modalities are accelerating the market growth. For example, researchers have developed a new imaging technique that may help eliminate the malignant tumour from the human body. This imaging method may help surgeons locate the tumour with ease. The method also involves using an infra-red (IR) camera and an imaging reagent tozuleristide (BLZ-100). The agent contains a synthetic version of an amino acid compound found in scorpion venom. The primary goal of this procedure was to distinguish between healthy and tumour tissue. This aids in the retention of healthy tissue following surgery, increasing the overall efficiency of the procedure . Such discoveries are likely to favour the growth of the global adult malignant glioma therapeutics market in the coming years.

 

Key Players in the Global Market for Adult Malignant Glioma Therapeutics

The report gives a detailed analysis of the following key players in the global adult malignant glioma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals, LLC
  • AbbVie Inc.
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diseases Type
  • Therapy Type
  • Drug Class
  • Route of Administration
  • Treatment Centers
  • Treatment Channel
  • Region
Breakup by Diseases Type
  • Glioblastoma Multiforme (GBM)
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Others
Breakup by Therapy Type
  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Tumor treating fields (TTF) Therapy
  • Combination Therapy
  • Others
Breakup by Drug Class
  • Alkylating Agents
  • Tyrosine Kinase Inhibitors
  • Checkpoint Inhibitors
  • Angiogenesis Inhibitors
  • Other
Breakup by Route of Administration
  • Oral
  • Parentals
  • Others
Breakup by Treatment Centers
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centres
  • Cancer Research Institutes
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Bayer AG
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Abbott
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Genetech Inc.
  • Emcure

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Adult Malignant Glioma Diseases Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Adult Malignant Glioma Epidemiology Analysis
    5.1    Overview (2016-2031)
    5.2    North America Adult Malignant Glioma Epidemiology (2016-2031)
    5.3    Europe Adult Malignant Glioma Epidemiology (2016-2031)
    5.4    Asia-Pacific Adult Malignant Glioma Epidemiology (2016-2031)
    5.5    Latin America Adult Malignant Glioma Epidemiology (2016-2031)
    5.6    Middle East & Africa Adult Malignant Glioma Epidemiology (2016-2031)
6    Global Adult Malignant Glioma Therapeutics Market Overview 
    6.1    Global Adult Malignant Glioma Therapeutics Market Historical Value (2017-2023) 
    6.2    Global Adult Malignant Glioma Therapeutics Market Forecast Value (2024-2032)
7    Global Adult Malignant Glioma Therapeutics Market Landscape
    7.1    Global Adult Malignant Glioma Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Adult Malignant Glioma Therapeutics: Product Landscape
        7.2.1    Analysis by Diseases Type
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by Treatment Channel
        7.2.5    Analysis by End User
8    Adult Malignant Glioma Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Adult Malignant Glioma Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Adult Malignant Glioma Therapeutics Market Segmentation
    11.1    Global Adult Malignant Glioma Therapeutics Market by Diseases Type
        11.1.1    Market Overview
        11.1.2    Glioblastoma Multiforme (GBM)
        11.1.3    Anaplastic Astrocytoma
        11.1.4    Anaplastic Oligodendroglioma
        11.1.5    Anaplastic Oligoastrocytoma
        11.1.6    Others
    11.2    Global Adult Malignant Glioma Therapeutics Market by Therapy Type
        11.2.1    Market Overview
        11.2.2    Surgery
        11.2.3    Radiation Therapy
        11.2.4    Chemotherapy
        11.2.5    Targeted Therapy
        11.2.6    Immunotherapy
        11.2.7    Tumor treating fields (TTF) Therapy
        11.2.8    Combination Therapy
        11.2.9    Others
    11.3    Global Adult Malignant Glioma Therapeutics Market by Drug Class
        11.3.1    Market Overview
        11.3.2    Alkylating Agents
        11.3.3    Tyrosine Kinase Inhibitors
        11.3.4    Checkpoint Inhibitors
        11.3.5    Angiogenesis Inhibitors
        11.3.6    Other
    11.4    Global Adult Malignant Glioma Therapeutics Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral 
        11.4.3    Parentals
        11.4.4    Others
    11.5    Global Adult Malignant Glioma Therapeutics Market by Treatment Centers
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Specialty Clinics
        11.5.4    Ambulatory Surgical Centres
        11.5.5    Cancer Research Institutes
        11.5.6    Others
    11.6    Global Adult Malignant Glioma Therapeutics Market by Treatment Channel
        11.6.1    Market Overview
        11.6.2    Public
        11.6.3    Private
    11.7    Global Adult Malignant Glioma Therapeutics Market by Region
        11.7.1    Market Overview
        11.7.2    North America
        11.7.3    Europe 
        11.7.4    Asia Pacific
        11.7.5    Latin America
        11.7.6    Middle East and Africa
12    North America Adult Malignant Glioma Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Adult Malignant Glioma Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Adult Malignant Glioma Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Adult Malignant Glioma Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Adult Malignant Glioma Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Mylan N.V.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Teva Pharmaceutical Industries Ltd.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Sanofi
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Pfizer Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    GlaxoSmithKline plc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Novartis AG
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Bayer AG
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Merck & Co., Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Allergan
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    AstraZeneca
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Johnson & Johnson Private Limited
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Abbott
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Bausch Health Companies Inc.
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Sun Pharmaceutical Industries Ltd.
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    Aurobindo Pharma
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
    23.16    Lupin
        23.16.1    Financial Analysis
        23.16.2    Product Portfolio
        23.16.3    Demographic Reach and Achievements
        23.16.4    Mergers and Acquisitions
        23.16.5    Certifications
    23.17    Amneal Pharmaceuticals LLC.
        23.17.1    Financial Analysis
        23.17.2    Product Portfolio
        23.17.3    Demographic Reach and Achievements
        23.17.4    Mergers and Acquisitions
        23.17.5    Certifications
    23.18    Genetech Inc.
        23.18.1    Financial Analysis
        23.18.2    Product Portfolio
        23.18.3    Demographic Reach and Achievements
        23.18.4    Mergers and Acquisitions
        23.18.5    Certifications
    23.19    Emcure
        23.19.1    Financial Analysis
        23.19.2    Product Portfolio
        23.19.3    Demographic Reach and Achievements
        23.19.4    Mergers and Acquisitions
        23.19.5    Certifications
24    Adult Malignant Glioma Therapeutics Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for adult malignant glioma therapeutics reached a value of USD 2.19 billion.

The market is anticipated to grow at a CAGR of 9.2% during the forecast period of 2024-2032 to reach a value of USD 4.85 million by 2032.

The major drivers of the market include the growing cases of brain tumours, adoption of an unhealthy lifestyle, excessive exposure to radiation, family history with brain cancer, fast-expanding pipeline of innovative novel medications, increased government support, and technological advancements.

The rising prevalence of cancer-related disorders and increased advancements in cancer treatment are the key industry trends propelling the growth of the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different therapies provided by the market are radiotherapy, chemotherapy, and targeted therapy, among others.

Based on disease, the market is divided into anaplastic astrocytoma, glioblastoma multiforme, and anaplastic oligodendroglioma, among others.

The end-uses of the market are speciality clinics, hospitals, and cancer and radiation therapy centres, among others.

The major players in the industry are Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, LLC, and AbbVie Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER